ENTtoday
  • Home
  • Practice Focus
    • Allergy
    • Facial Plastic/Reconstructive
    • Head and Neck
    • Laryngology
    • Otology/Neurotology
    • Pediatric
    • Rhinology
    • Sleep Medicine
  • Departments
    • Issue Archive
    • TRIO Best Practices
      • Allergy
      • Facial Plastic/Reconstructive
      • Head and Neck
      • Laryngology
      • Otology/Neurotology
      • Pediatric
      • Rhinology
      • Sleep Medicine
    • Career Development
    • Case of the Month
    • Everyday Ethics
    • Health Policy
    • Legal Matters
    • Letter From the Editor
    • Medical Education
    • Online Exclusives
    • Practice Management
    • Resident Focus
    • Rx: Wellness
    • Special Reports
    • Tech Talk
    • Viewpoint
    • What’s Your O.R. Playlist?
  • Literature Reviews
    • Allergy
    • Facial Plastic/Reconstructive
    • Head and Neck
    • Laryngology
    • Otology/Neurotology
    • Pediatric
    • Rhinology
    • Sleep Medicine
  • Multimedia
    • Video
    • Audio
  • Events
    • Featured Events
    • TRIO Meetings
  • Contact Us
    • About Us
    • Editorial Board
    • Triological Society
    • Advertising Staff
    • Subscribe
  • Advertise
    • Place an Ad
    • Classifieds
    • Rate Card
  • Search

Drug Marketing: Different Impacts on Different Physicians

by Marlene Piturro, PhD, MBA • December 1, 2006

  • Tweet
  • Email
Print-Friendly Version

Pharmaceutical company representatives (PCRs) are as ubiquitous in otolaryngologists’ offices as seasonal allergies and ear infections. Their job during their marketing visits, commonly referred to as “detailing,” is to get physicians to write more prescriptions for their products. But there is more to friendly PCR visits than meets the eye, as Sridhar Narayanan, PhD, an assistant professor of marketing at Stanford University’s Graduate School of Business, has shown. Several studies of the marketing of second-generation antihistamines to both physicians and consumers have demonstrated that pharmaceutical companies, assisted by health care information organizations (HIOs), use marketing tools fashioned from massaging databases of individual physician prescribing data to get them to expand demand for drug categories.

You Might Also Like

  • When It Comes to Drug Development, What Do Our Dollars Buy?
  • AMA’s Opt-Out Provision for Sale of Physician Prescribing Data Seen as First Step
  • Prescription Drug Benefit Primer
  • Rising Drug Costs Create Concern About Drug Diversions
Explore This Issue
December 2006

Among Professor Narayanan’s more intriguing findings on marketing second-generation antihistamines is that “fast learning” doctors increase the number of prescriptions written after only two or three visits from PCRs, whereas the “slow learners” take 17 or 18 visits to catch on. “Drug companies rely on HIO data to detect the fast and slow learners because physician surveys about prescribing tend to be problematic. Data on prescribing patterns coupled with detailing visits geared to differences in physician learning rates often spells the difference between heavy and light prescribers,” says Prof. Narayanan. It’s all part of the $8.5 billion that pharmaceutical companies spend annually marketing to consumers and physicians.

For John Krouse, MD, PhD, professor and vice-chair, director of Rhinology/Allergy in Detroit-based Wayne State University’s Department of Otolaryngology–Head and Neck Surgery, the data-driven approach may account for the canned spiels that aggressive PCRs use to steer the conversation their way. “I prefer PCRs who act professionally, are well educated, and want a good ongoing relationship with the physicians. It doesn’t take long to figure out which PCRs are only pushing product and which are the ones who can build a relationship on trust and comfort,” he says.

Prof. Narayanan’s research also indicates that some managers, having front-loaded both direct-to-consumer advertising (DTCA) and detailing months before a product’s launch and in the year immediately following increased revenues by 4 to 14%, a strategy that other pharmaceutical companies should have followed to achieve similar results. Dr. Krouse counters that seasoned otolaryngologists are familiar with drugs in the pipeline and would like a collegial conversation with PCRs rather than a hard-sell about the new product. Prof. Narayanan also found in subsequent research that detailing and DTCA have long-term effects on revenues that are four to seven times the current-period effects. Apparently, persistence pays off in pharmaceutical marketing, encouraging PCRs to keep hammering away at physicians to keep their prescription-writing pens busy.

Pages: 1 2 3 | Single Page

Filed Under: Departments, Everyday Ethics, Health Policy, Medical Education, Practice Management Tagged With: Ethics, healthcare reform, marketing, medical education, medication, pharmaceuticals, policy, residentsIssue: December 2006

You Might Also Like:

  • When It Comes to Drug Development, What Do Our Dollars Buy?
  • AMA’s Opt-Out Provision for Sale of Physician Prescribing Data Seen as First Step
  • Prescription Drug Benefit Primer
  • Rising Drug Costs Create Concern About Drug Diversions

The Triological SocietyENTtoday is a publication of The Triological Society.

The Laryngoscope
Ensure you have all the latest research at your fingertips; Subscribe to The Laryngoscope today!

Laryngoscope Investigative Otolaryngology
Open access journal in otolaryngology – head and neck surgery is currently accepting submissions.

Classifieds

View the classified ads »

TRIO Best Practices

View the TRIO Best Practices »

Top Articles for Residents

  • Do Training Programs Give Otolaryngology Residents the Necessary Tools to Do Productive Research?
  • Why More MDs, Medical Residents Are Choosing to Pursue Additional Academic Degrees
  • What Physicians Need to Know about Investing Before Hiring a Financial Advisor
  • Tips to Help You Regain Your Sense of Self
  • Should USMLE Step 1 Change from Numeric Score to Pass/Fail?
  • Popular this Week
  • Most Popular
  • Most Recent
    • The Dramatic Rise in Tongue Tie and Lip Tie Treatment
    • Vertigo in the Elderly: What Does It Mean?
    • Is There a Crisis in the Otolaryngology Match?
    • New Developments in the Management of Eustachian Tube Dysfunction
    • Experts Delve into Treatment Options for Laryngopharyngeal Reflux
    • New Developments in the Management of Eustachian Tube Dysfunction
    • Vertigo in the Elderly: What Does It Mean?
    • Eustachian Tuboplasty: A Potential New Option for Chronic Tube Dysfunction and Patulous Disease
    • Some Laryngopharyngeal Reflux Resists PPI Treatment
    • Post-Tonsillectomy Taste Disorders Rare but Present
    • 10 Novel Ways to Disseminate Scientific Information
    • How to Work with Sales and Marketing Representatives in Your Medical Practice
    • How Medicine Helped Surgeon Prepare for Career as Writer
    • Best Practices for Emergency Surgical Airway
    • Spare Roof Technique Can Improve Patient Quality of Life after Rhinoplasty

Polls

Will registry information and data science improve patient care?

View Results

Loading ... Loading ...
  • Polls Archive
  • Home
  • Contact Us
  • Advertise
  • Privacy Policy
  • Terms of Use

Visit: The Triological Society • The Laryngoscope • Laryngoscope Investigative Otolaryngology

Wiley
© 2019 The Triological Society. All Rights Reserved.
ISSN 1559-4939

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.